- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CERO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Mo | Cero Therapeutics registers up to 12.5M shares for potential sale under equity agreement with Keystone | 1 | Seeking Alpha | ||
| Mo | CERO THERAPEUTICS HOLDINGS, INC. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| Fr | Cero Therapeutics schließt weitere Tranche der Serie-D-Finanzierung ab | 3 | Investing.com Deutsch | ||
| Fr | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.07. | Cero Therapeutics schließt Aktienkaufvereinbarung über 17,5 Mio. US-Dollar ab | 3 | Investing.com Deutsch | ||
| 08.07. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.06. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 23.06. | CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236 | 141 | GlobeNewswire (Europe) | SOUTH SAN FRANSCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) ("CERo" or the "Company"), an immunotherapy company developing the next generation of... ► Artikel lesen | |
| 23.06. | Cero Therapeutics-Aktie auf "Kaufen" hochgestuft dank Ansatz für solide Tumore | 3 | Investing.com Deutsch | ||
| 23.06. | Cero Therapeutics stock rating upgraded to Buy on solid tumor approach | 2 | Investing.com | ||
| 17.06. | CERo Therapeutics stock soars after FDA grants Orphan Drug Designation | 6 | Investing.com | ||
| 17.06. | CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML) | 268 | GlobeNewswire (Europe) | SOUTH SAN FRANSCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the... ► Artikel lesen | |
| 13.06. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.06. | CERo Therapeutics announces 1-for-20 reverse stock split effective June 13 | 3 | Seeking Alpha | ||
| 11.06. | CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split | 189 | GlobeNewswire (Europe) | SOUTH SAN FRANSCISCO, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the... ► Artikel lesen | |
| 06.06. | CERo Therapeutics gibt zusätzliche Serie-D-Aktien aus | 2 | Investing.com Deutsch | ||
| 06.06. | CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 06.06. | CERo Therapeutics issues additional Series D stock | 1 | Investing.com | ||
| 06.06. | CERo Therapeutics Holdings, Inc.: CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing | 1 | GlobeNewswire (USA) | ||
| 02.06. | Maxim Group Maintains Buy Rating on CERo Therapeutics (CERO) | 1 | Insider Monkey |
1 2 3 4 Weiter >>
76 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,200 | -16,85 % | Evotec, Hugo Boss, Lanxess, Nagarro, SMA Solar, Zalando - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| QIAGEN | 41,050 | -0,86 % | Dividendenbekanntmachungen (10.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCENTURE PLC IE00B4BNMY34 1,48 USD 1,2626 EUR AT&T INC US00206R1023 0,2775 USD 0,2367 EUR AZZ INC US0024741045 0,2 USD 0,1706... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,380 | 0,00 % | Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? | ||
| ITEOS THERAPEUTICS | 10,135 | 0,00 % | iTeos Therapeutics Inc.: iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right | WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. ("iTeos") (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement... ► Artikel lesen | |
| BIONTECH | 93,05 | -1,69 % | DAX-Korrektur! BioTech Im Übernahme-Modus! BioNTech, CureVac, Pfizer, Vidac Pharma und Kraft Heinz im Fokus | Die Aktienmärkte zeigen sich in Bestform: Sowohl der DAX als auch der NASDAQ 100 haben in den vergangenen Tagen Muskeln gezeigt. Angetrieben werden die Kurse vor allem von der anhaltenden Stärke der... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 55,50 | -0,89 % | CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading | ||
| AVIDITY BIOSCIENCES | 34,040 | +0,89 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants | -- Unprecedented data from FORTITUDE dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,020 | 0,00 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 26,340 | +0,53 % | Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings | ||
| SAB BIOTHERAPEUTICS | 2,655 | 0,00 % | SAB Biotherapeutics sichert sich 175 Mio. US-Dollar über Privatplatzierung - Aktie legt um 33 % zu | ||
| REDHILL BIOPHARMA | 2,380 | 0,00 % | RedHill Biopharma Ltd.: RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease | The positive FDA feedback allows for:
A novel Phase 2 RHB-204[1] study, planned to be the first ever clinical study in a specifically defined Mycobacterium avium... ► Artikel lesen | |
| 180 LIFE SCIENCES | 2,800 | 0,00 % | 180 Life Sciences beschleunigt Zuteilung von Aktienvergütungen für Führungskräfte | ||
| ABSCI | 3,505 | 0,00 % | Absci Corporation: Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease | Absci becomes clinical stage company with ABS-101, first AI-designed biologic for IBD, beginning Phase 1 trial Preclinical data for ABS-101 demonstrates high potency and potential for quarterly dosing... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,130 | +2,39 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 35,210 | +0,11 % | Truist Securities initiates Harmony Biosciences stock with Buy rating |
CERO THERAPEUTICS HOLDINGS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 8,460 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CERO THERAPEUTICS HOLDINGS INC finden Sie auf Wallstreet Online.